)
Visual
test
Strides Pharma Science
Strides Pharma Science (STAR) investor relations material
Strides Pharma Science Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary30 Jan, 2026
Executive summary
Achieved highest ever quarterly EBITDA of ₹2,359m in Q3FY26, with operational PAT at ₹1,282m and EPS at ₹13.9, up 39% year-on-year; gross margins reached 59.8%–61.2% and ex-U.S. markets contributed 47% of revenue with 20% YoY growth.
U.S. business remained flat due to delayed flu season and product discontinuations, but long-term growth drivers remain intact.
Leadership strengthened with appointment of new CEO for North America and EVP of HR to drive growth and organizational capability.
ESG/Sustainability score improved by 5 points to 80, reflecting focus on responsible growth and governance.
Major one-time gain of Rs. 31,881.07 million recognized from the demerger of the CDMO and Soft Gelatin business, presented as discontinued operations.
Financial highlights
Q3FY26 revenue reached ₹11,946m, up 3.6% YoY; gross margin improved to 61.2% (+280bps YoY); EBITDA margin rose to 19.8% (+160bps YoY).
Operational PAT rose 39% YoY to ₹1,282m; reported PAT for the quarter at ₹2,081m, including gain from sale of investment property.
For nine months, operational PAT grew 65% YoY to ₹3,824m, exceeding full FY25 PAT.
Cash to cash cycle stable at 124 days; operational cash flow for nine months at ₹4,841m (70% EBITDA to operating cash conversion).
Basic EPS for continuing operations for the quarter was Rs. 21.93, compared to Rs. 9.56 in the prior year quarter.
Outlook and guidance
U.S. business revenue outlook reiterated at ~$400m by FY28, with ex-U.S. markets expected to mirror U.S. size in two years, driven by portfolio expansion and new customer acquisitions.
Growth to be driven by relaunch of dormant products, investments in complex generics, and expansion in regulated and growth markets.
CapEx guidance: ₹1,000–1,250m for maintenance, with additional opportunistic investments in global product rights.
Tax rate expected in the 15%–18% range for the year.
Focus remains on operating cashflow generation and continued debt reduction while funding capex from internal accruals.
How will new CEO and investments drive US growth
Sustain ex-US growth: what specific levers are key
Cash-to-cash cycle: how to manage ex-US impact
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Strides Pharma Science earnings date
Q4 25/2622 May, 2026
Strides Pharma Science
Next Strides Pharma Science earnings date
Q4 25/2622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Strides Pharma Science Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of generic medicines. The company specializes in niche and complex formulations across various therapeutic areas, including antibiotics, oncology, central nervous system, and dermatology. It operates a global network of manufacturing facilities and supplies products to regulated markets, including the United States, Europe, and emerging economies. The company is headquartered in Bengaluru, India, and its shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage